Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin

NCT ID: NCT00622648

Last Updated: 2010-12-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 8329 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2010-12-31

Brief Summary

The primary objective:

• To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization.

The secondary objective:

• To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization.
• To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .

Conditions

Acute Illness

Keywords

Medical prevention therapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

A

Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)

Group Type: EXPERIMENTAL

Enoxaparin

Intervention Type: DRUG

40 mg once daily for 6 to 14 days (10 ± 4 days)

B

Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

Interventions

Enoxaparin

40 mg once daily for 6 to 14 days (10 ± 4 days)

Intervention Type: DRUG

Placebo

Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Hospitalization within 48 hours prior randomization for at least one of the following medical acute medical illness:

• Acute decompensation of heart failure
• Severe systemic infection and at least one of the following:

• Chronic pulmonary diseases (COPD, pulmonary fibrosis, pulmonary restrictive syndrome…)
• Obesity (BMI ≥ 30kg/m2)
• Personal history of VTE
• Age ≥ 60 years
• Active cancer (defined as being histologically confirmed with an initial diagnosis or recurrence or metastasis within the past 6 months) excluding planned hospitalization for chemotherapy
• Anticipated duration of hospitalization at least 6 days
• Health status:

• ASA Health status score ≤ 3 (American Society of Anesthesiologists)
• ECOG ≤ 2 in cancer patient
• Anticipated life expectancy > 1 week

Exclusion Criteria

• Major surgery or major trauma within the previous 6 weeks (orthopedic or trauma surgery to the lower extremities, gastrointestinal tract, urological, chest, gynecological surgery)
• Need for any ventilatory support (with intubation required)
• Symptomatic VTE at enrollment
• Multi organ failure
• Evidence of an active bleeding disorder
• Contraindication to anticoagulation:

• Coagulopathy (acquired or inherited)
• Neurosurgery within the past day 30
• History of cerebral hemorrhage at any time
• Known bacterial endocarditis
• Uncontrolled arterial hypertension (systolic BP > 200 mmHg or diastolic BP > 110 mm Hg) at 2 successive readings
• Haemostatic abnormalities: baseline platelet count <50,000/mm3, activated partial thromboplastin time (aPTT) 1.5x the upper limit of normal, or International Normalized Ratio (INR) > 1.5
• Indication for thrombolytic therapy
• Need for a curative treatment of anticoagulant therapy (low molecular weight heparin, unfractionated heparin, oral anticoagulant therapy)
• Receiving LMWH or UFH at prophylactic doses for more than 72 hours prior to inclusion (patients receiving LMWH or UFH at prophylactic doses for 72 hours or less prior to entry may be included in the study)
• Oral anticoagulant therapy within 72 hours prior to inclusion
• Cerebrovascular accident at inclusion and within 10 days prior study inclusion
• Prosthetic heart valves
• Confirmed cerebral metastases
• Known hypersensitivity to heparin or LMWH, or pork-derived products
• History of documented episode of heparin, or LMWH induced thrombocytopenia, and/or thrombosis (HIT, HAT, or HITTS)
• Participating in another clinical trial within the previous 30 days (patients with cancer included in a cancer treatment protocol are authorized to participate)
• Persistent renal failure (defined as a documented value of calculated creatinine clearance < 30 mL/min on at least 2 occasions ³3 days prior to entry into the study)
• Known or suspected severe anemia of unexplained cause considered clinically relevant by investigator
• Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
• Unlikely to be compliant (e.g. alcohol, drug abuse)
• Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling to be tested for pregnancy (pregnancy status should be checked by serum or urine pregnancy testing prior to exposure to the investigational product)
• Refusal or inability to give informed consent to participate in the study
• Inability to be followed-up after discharge until day 90 after randomization

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Sanofi-aventis

Principal Investigators

Bruno DESLANDES

Role: STUDY_DIRECTOR

Sanofi

Locations

Sanofi-Aventis Administrative Office

São Paulo, , Brazil

Sanofi-Aventis Administrative Office

Shanghai, , China

Sanofi-Aventis Administrative Office

Hong Kong, , Hong Kong

Sanofi-Aventis Administrative Office

Mumbai, , India

Sanofi-Aventis Administrative Office

Kuala Lumpur, , Malaysia

Sanofi-Aventis Administrative Office

Col. Coyoacan, , Mexico

Sanofi-Aventis Administrative Office

Makati City, , Philippines

Sanofi-Aventis Administrative Office

Seoul, , South Korea

Sanofi-Aventis Administrative Office

Mégrine, , Tunisia

Countries

Brazil; China; Hong Kong; India; Malaysia; Mexico; Philippines; South Korea; Tunisia

References

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.

Reference Type: DERIVED

PMID: 22204723 (View on PubMed)

Other Identifiers

ENOXA_C_01249

Identifier Type: -

Identifier Source: org_study_id